Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.88 |
| ▸ | TSHR | P16473 | 3/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546827 | 0.96 | POLB (0.87) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL5314300 | 0.89 | KMT2A (0.81) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL6962582 | 0.84 | POLB (0.67) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL3176249 | 0.84 | KDM4E (1.00) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL9028142 | 0.84 | POLB (0.67) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL10751242 | 0.81 | — | — | |
| SCHEMBL2422007 | 0.80 | POLB (0.61) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL16439724 | 0.80 | KDM4E (0.95) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL18713004 | 0.80 | POLB (0.70) | POLBKMT2ATSHRKDM4ECA1 | |
| SCHEMBL21356989 | 0.76 | CA1 (1.00) | POLBKMT2ATSHRKDM4ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11165097-B2 | Electrolyte, electrochemical device and electronic device containing the same | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20200243905-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE CONTAINING THE SAME | NINGDE AMPEREX TECHNOLOGY LIMITED | 2020-07-30 | — | — | US | disclosed |
| EP-1784399-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021457-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6825354-B2 | OSTEOPOROSIS; RHEUMATIC DISEASES | WYETH HOLDINGS CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
| EP-1147080-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6753337-B2 | INHIBITORS OF TNF-ALPHA CONVERTING ENZYME; TREATMENT OF ARTHRITIS, INFLAMMATION, INFLAMMATORY BOWEL DISEASE ETC, | WYETH HOLDINGS CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | AMERICAN CYANAMID COMPANY | 2002-07-04 | — | — | US | disclosed |
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6340691-B1 | TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0650474-A1 | NOVEL PIPERIDYL AMIDES, SULFONAMIDES AND SULFOXAMIDES AS INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | MERRELL PHARMACEUTICALS INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994001404-A1 | NOVEL PIPERIDYL AMIDES, SULFONAMIDES AND SULFOXAMIDES AS INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-4649167-A | STABILIZERS FOR POLYMERS AGAINST RADIATION DEGRADATION | PENNWALT CORPORATION (US) | 1987-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | MMP17, MMP1, MMP9 | POLB 563/4885KMT2A 2963/4885TSHR 3196/4885 |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | POLB 563/4885KMT2A 2963/4885TSHR 3196/4885 |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | POLB 928/4885KMT2A 2668/4885TSHR 4106/4885 |
| US-11165097-B2 | Electrolyte, electrochemical device and electronic device containing the same | CA3, SCNN1G, SCN10A | POLB 2163/4885KMT2A 940/4885TSHR 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.